Henning Scheich
Fondateur chez Leibniz Institute for Neurobiology
Profil
Henning Scheich was the founder of KeyNeurotek Pharmaceuticals AG, where he served as Director-Supervisory Board from 2009 to 2011.
He is also the founder of Leibniz Institute for Neurobiology.
Currently, he holds a position as a Member at Germany Ministry of Education & Research.
Postes actifs de Henning Scheich
| Sociétés | Poste | Début |
|---|---|---|
| Leibniz Institute for Neurobiology | Fondateur | 31/08/2009 |
| Germany Ministry of Education & Research | Corporate Officer/Principal | 31/08/2009 |
Anciens postes connus de Henning Scheich
| Sociétés | Poste | Fin |
|---|---|---|
KeyNeurotek Pharmaceuticals AG
 KeyNeurotek Pharmaceuticals AG Pharmaceuticals: OtherHealth Technology KeyNeurotek Pharmaceuticals AG is a biopharmaceutical company focused on the development of innovative small molecule drugs for the treatment of neuronal and autoimmune diseases. KeyNeurotek’s drug portfolio covers the entire drug development chain from research stage to advanced clinical development. At present, two compounds are in clinical development, KN38-7271 and KN203, both addressing significant markets such as traumatic brain injury, TBI, stroke, and urinary incontinence/overactive bladder. The company’s product development is based on its proprietary technology platform, which has been specifically tailored to diseases of the central nervous system, TELOMICS. KeyNeurotek was founded by Dr Frank Striggow, Frank Baumgart, Prof Dr Klaus G. Reymann and Prof Dr Henning Scheich in May 2000. The company is located in Magdeburg, Germany. | Fondateur | 03/08/2011 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
KeyNeurotek Pharmaceuticals AG
KeyNeurotek Pharmaceuticals AG Pharmaceuticals: OtherHealth Technology KeyNeurotek Pharmaceuticals AG is a biopharmaceutical company focused on the development of innovative small molecule drugs for the treatment of neuronal and autoimmune diseases. KeyNeurotek’s drug portfolio covers the entire drug development chain from research stage to advanced clinical development. At present, two compounds are in clinical development, KN38-7271 and KN203, both addressing significant markets such as traumatic brain injury, TBI, stroke, and urinary incontinence/overactive bladder. The company’s product development is based on its proprietary technology platform, which has been specifically tailored to diseases of the central nervous system, TELOMICS. KeyNeurotek was founded by Dr Frank Striggow, Frank Baumgart, Prof Dr Klaus G. Reymann and Prof Dr Henning Scheich in May 2000. The company is located in Magdeburg, Germany. | Health Technology |
| Leibniz Institute for Neurobiology | |
| Germany Ministry of Education & Research | Government |
